Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | IDE | P14735 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HLCS | P50747 | 6/20 | 0.53 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23124403 | 1.00 | TDP1 (0.57) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL29531755 | 0.94 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL3648687 | 0.90 | TDP1 (0.53) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL8597261 | 0.88 | TDP1 (0.51) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL2232070 | 0.87 | TDP1 (0.56) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL7906513 | 0.87 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL20537346 | 0.86 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL28653646 | 0.86 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL25305424 | 0.86 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL15104961 | 0.85 | TDP1 (0.68) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336747-B2 | Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells | Université de Montréal | 2019-07-02 | — | — | US | disclosed |
| EP-2807165-B1 | PYRIMIDO[4,5-B]INDOLE DERIVATIVES AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS | UNIV MONTREAL (CA) | 2019-05-15 | — | — | EP | disclosed |
| US-10172905-B1 | Treatment of protein degradation disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-01-08 | — | — | US | disclosed |
| EP-3354265-A1 | TREATMENT OF SOLID TUMORS | President and Fellows of Harvard College (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3338807-A1 | TARGETING CONSTRUCT FOR GAS-FILLED MICROVESICLES | Bracco Suisse SA (CH) | 2018-06-27 | — | — | EP | disclosed |
| EP-2491926-B1 | Treatment of protein degradation disorders | HARVARD COLLEGE (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20170334904-A1 | PYRIMIDO[4,5-B]INDOLE DERIVATIVES AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS | Université de Montréal (CA) | 2017-11-23 | — | — | US | disclosed |
| US-9572854-B2 | Treatment of protein degradation disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-02-21 | — | — | US | disclosed |
| US-9409906-B2 | Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells | UNIVERSITE DE MONTREAL (CA) | 2016-08-09 | — | — | US | disclosed |
| US-20160222017-A1 | PYRIMIDO[4,5-B]INDOLE DERIVATIVES AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS | Université de Montréal (CA) | 2016-08-04 | — | — | US | disclosed |
| US-5432288-A | Useful in effecting calcium efflux in tissue | INDIANA UNIVERSITY FOUNDATION (US) | 1995-07-11 | — | — | US | disclosed |
| WO-1994017447-A1 | CHEMICAL FUNCTIONALIZATION OF SURFACES | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 1994-08-04 | — | — | WO | disclosed |
| EP-0590563-A1 | Biotin amides, a process for their preparation and therapeutical compositions containing them as the active principles for the treatment of diabetes and relative complicating diseases | LIFEGROUP S.p.A. (IT) | 1994-04-06 | — | — | EP | disclosed |
| US-5280015-A | 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-01-18 | — | — | US | disclosed |
| WO-1992018499-A1 | NOVEL ESTER DERIVATIVES OF RYANODINE AND DEHYDRORYANODINE | INDIANA UNIVERSITY FOUNDATION (US) | 1992-10-29 | — | — | WO | disclosed |
| US-5059421-A | Stable protein-liposome conjugate exhibiting an absence of aggregation | THE LIPOSOME COMPANY, INC. (US) | 1991-10-22 | — | — | US | disclosed |
| WO-1991000289-A2 | TARGETED LIPOSOMES AND METHODS FOR LIPOSOME-PROTEIN COUPLING | THE LIPOSOME COMPANY, INC. (US) | 1991-01-10 | — | — | WO | disclosed |
| EP-0396692-A1 | A METHOD OF ASSAYING AN ENZYME AND KIT AND SUBSTANCES SUITABLE FOR THAT METHOD | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk onderzoek TNO (NL) | 1990-11-14 | — | — | EP | disclosed |
| WO-1990005309-A1 | A METHOD OF ASSAYING AN ENZYME AND KIT AND SUBSTANCES SUITABLE FOR THAT METHOD | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 1990-05-17 | — | — | WO | disclosed |
| WO-1989009835-A1 | LIGASE-BASED AMPLIFICATION METHOD | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1989-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172905-B1 | Treatment of protein degradation disorders | HDAC6, HDAC5, AADAC | TDP1 404/4885MEN1 3426/4885ABL1 1273/4885 |
| US-20160222017-A1 | PYRIMIDO[4,5-B]INDOLE DERIVATIVES AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS | IDO1, IDO2, INMT | TDP1 2505/4885MEN1 3036/4885ABL1 36/4885 |
| US-10336747-B2 | Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells | IDO1, IDO2, INMT | TDP1 2505/4885MEN1 3036/4885ABL1 36/4885 |
| US-20170334904-A1 | PYRIMIDO[4,5-B]INDOLE DERIVATIVES AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS | IDO1, IDO2, INMT | TDP1 2505/4885MEN1 3036/4885ABL1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.